Masaki N, Ikeda H, Matayoshi Y, Murayama S, Fujita M, Kozuka T
Dept. of Radiology, Osaka Univ. Med. School.
Gan No Rinsho. 1989 Oct;35(13):1591-5.
Advances in staging and more refined radiation techniques and the combination chemotherapy have lead marked improvement of survival of patients with Hodgkin's disease and non-Hodgkin's lymphoma. The important prognostic factors used for choosing treatment programs are stage, histology, tumor bulk and the site of involvement for patients with early stage disease. Tumor bulk is considered as an important variable when patients are treated with radiation therapy alone. However, aggressive staging and effective therapy tend to obscure the differences in survival and relapse-free survival that would be observed in untreated patients and may be difficult to identify prognostic factors.
分期、更精确的放疗技术以及联合化疗方面的进展显著提高了霍奇金淋巴瘤和非霍奇金淋巴瘤患者的生存率。对于早期疾病患者，用于选择治疗方案的重要预后因素包括分期、组织学类型、肿瘤体积和受累部位。当仅对患者进行放射治疗时，肿瘤体积被视为一个重要变量。然而，积极的分期和有效的治疗往往会掩盖在未治疗患者中观察到的生存和无复发生存差异，可能难以识别预后因素。
